Reviews Everolimus


No reviews yet.

Zortress Drug Description
Zortress (everolimus)

WARNING
WARNING IMMUNOSUPPRESSION, RENAL FUNCTION, AND GRAFT THROMBOSIS

Increased susceptibility to infection and the possible development of malignancies
such as lymphoma and skin cancer may result from immunosuppression. [See WARNINGS AND PRECAUTIONS]
Only physicians experienced in immunosuppressive therapy and management
of transplant patients should prescribe Zortress. Patients receiving the drug
should be managed in facilities equipped and staffed with adequate laboratory
and supportive medical resources. The physician responsible for maintenance
therapy should have complete information requisite for the follow-up of the
patient. [See WARNINGS AND PRECAUTIONS]
Increased nephrotoxicity can occur with use of standard doses of cyclosporine
in combination with everolimus. Therefore reduced doses of cyclosporine should
be used in combination with everolimus in order to reduce renal dysfunction.
It is important to monitor the cyclosporine and everolimus whole blood trough
concentrations. [See DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS
and CLINICAL PHARMACOLOGY]
An increased risk of kidney arterial and venous thrombosis, resulting in
graft loss, was reported, mostly within the first 30 days post-transplantation.
[See WARNINGS AND PRECAUTIONS]


DRUG DESCRIPTION
Zortress (everolimus) is a macrolide immunosuppressant.
The chemical name of everolimus is
(1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1,
18-dihydroxy-12 -{(1R)- 2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,
17, 21, 23, 29, 35-hexamethyl-11, 36-dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2,
3,10,14,20-pentaone.
The molecular formula is C53H83NO14 and the
molecular weight is 958.25. The structural formula is








Everolimus is supplied as tablets for oral administration containing 0.25 mg,
0.5 mg and 0.75 mg of everolimus together with butylated hydroxytoluene, magnesium
stearate, lactose monohydrate, hypromellose, crospovidone and lactose anhydrous
as inactive ingredients.
Last reviewed on RxList: 5/6/2010




Zortress Drug Description
Zortress (everolimus)

WARNING
WARNING IMMUNOSUPPRESSION, RENAL FUNCTION, AND GRAFT THROMBOSIS

Increased susceptibility to infection and the possible development of malignancies
such as lymphoma and skin cancer may result from immunosuppression. [See WARNINGS AND PRECAUTIONS]
Only physicians experienced in immunosuppressive therapy and management
of transplant patients should prescribe Zortress. Patients receiving the drug
should be managed in facilities equipped and staffed with adequate laboratory
and supportive medical resources. The physician responsible for maintenance
therapy should have complete information requisite for the follow-up of the
patient. [See WARNINGS AND PRECAUTIONS]
Increased nephrotoxicity can occur with use of standard doses of cyclosporine
in combination with everolimus. Therefore reduced doses of cyclosporine should
be used in combination with everolimus in order to reduce renal dysfunction.
It is important to monitor the cyclosporine and everolimus whole blood trough
concentrations. [See DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS
and CLINICAL PHARMACOLOGY]
An increased risk of kidney arterial and venous thrombosis, resulting in
graft loss, was reported, mostly within the first 30 days post-transplantation.
[See WARNINGS AND PRECAUTIONS]


DRUG DESCRIPTION
Zortress (everolimus) is a macrolide immunosuppressant.
The chemical name of everolimus is
(1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1,
18-dihydroxy-12 -{(1R)- 2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,
17, 21, 23, 29, 35-hexamethyl-11, 36-dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2,
3,10,14,20-pentaone.
The molecular formula is C53H83NO14 and the
molecular weight is 958.25. The structural formula is








Everolimus is supplied as tablets for oral administration containing 0.25 mg,
0.5 mg and 0.75 mg of everolimus together with butylated hydroxytoluene, magnesium
stearate, lactose monohydrate, hypromellose, crospovidone and lactose anhydrous
as inactive ingredients.
Last reviewed on RxList: 5/6/2010




Zortress Drug Description
Zortress (everolimus)

WARNING
WARNING IMMUNOSUPPRESSION, RENAL FUNCTION, AND GRAFT THROMBOSIS

Increased susceptibility to infection and the possible development of malignancies
such as lymphoma and skin cancer may result from immunosuppression. [See WARNINGS AND PRECAUTIONS]
Only physicians experienced in immunosuppressive therapy and management
of transplant patients should prescribe Zortress. Patients receiving the drug
should be managed in facilities equipped and staffed with adequate laboratory
and supportive medical resources. The physician responsible for maintenance
therapy should have complete information requisite for the follow-up of the
patient. [See WARNINGS AND PRECAUTIONS]
Increased nephrotoxicity can occur with use of standard doses of cyclosporine
in combination with everolimus. Therefore reduced doses of cyclosporine should
be used in combination with everolimus in order to reduce renal dysfunction.
It is important to monitor the cyclosporine and everolimus whole blood trough
concentrations. [See DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS
and CLINICAL PHARMACOLOGY]
An increased risk of kidney arterial and venous thrombosis, resulting in
graft loss, was reported, mostly within the first 30 days post-transplantation.
[See WARNINGS AND PRECAUTIONS]


DRUG DESCRIPTION
Zortress (everolimus) is a macrolide immunosuppressant.
The chemical name of everolimus is
(1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1,
18-dihydroxy-12 -{(1R)- 2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,
17, 21, 23, 29, 35-hexamethyl-11, 36-dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2,
3,10,14,20-pentaone.
The molecular formula is C53H83NO14 and the
molecular weight is 958.25. The structural formula is








Everolimus is supplied as tablets for oral administration containing 0.25 mg,
0.5 mg and 0.75 mg of everolimus together with butylated hydroxytoluene, magnesium
stearate, lactose monohydrate, hypromellose, crospovidone and lactose anhydrous
as inactive ingredients.
Last reviewed on RxList: 5/6/2010




Zortress Drug Description
Zortress (everolimus)

WARNING
WARNING IMMUNOSUPPRESSION, RENAL FUNCTION, AND GRAFT THROMBOSIS

Increased susceptibility to infection and the possible development of malignancies
such as lymphoma and skin cancer may result from immunosuppression. [See WARNINGS AND PRECAUTIONS]
Only physicians experienced in immunosuppressive therapy and management
of transplant patients should prescribe Zortress. Patients receiving the drug
should be managed in facilities equipped and staffed with adequate laboratory
and supportive medical resources. The physician responsible for maintenance
therapy should have complete information requisite for the follow-up of the
patient. [See WARNINGS AND PRECAUTIONS]
Increased nephrotoxicity can occur with use of standard doses of cyclosporine
in combination with everolimus. Therefore reduced doses of cyclosporine should
be used in combination with everolimus in order to reduce renal dysfunction.
It is important to monitor the cyclosporine and everolimus whole blood trough
concentrations. [See DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS
and CLINICAL PHARMACOLOGY]
An increased risk of kidney arterial and venous thrombosis, resulting in
graft loss, was reported, mostly within the first 30 days post-transplantation.
[See WARNINGS AND PRECAUTIONS]


DRUG DESCRIPTION
Zortress (everolimus) is a macrolide immunosuppressant.
The chemical name of everolimus is
(1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1,
18-dihydroxy-12 -{(1R)- 2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,
17, 21, 23, 29, 35-hexamethyl-11, 36-dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2,
3,10,14,20-pentaone.
The molecular formula is C53H83NO14 and the
molecular weight is 958.25. The structural formula is








Everolimus is supplied as tablets for oral administration containing 0.25 mg,
0.5 mg and 0.75 mg of everolimus together with butylated hydroxytoluene, magnesium
stearate, lactose monohydrate, hypromellose, crospovidone and lactose anhydrous
as inactive ingredients.
Last reviewed on RxList: 5/6/2010




Zortress Drug Description
Zortress (everolimus)

WARNING
WARNING IMMUNOSUPPRESSION, RENAL FUNCTION, AND GRAFT THROMBOSIS

Increased susceptibility to infection and the possible development of malignancies
such as lymphoma and skin cancer may result from immunosuppression. [See WARNINGS AND PRECAUTIONS]
Only physicians experienced in immunosuppressive therapy and management
of transplant patients should prescribe Zortress. Patients receiving the drug
should be managed in facilities equipped and staffed with adequate laboratory
and supportive medical resources. The physician responsible for maintenance
therapy should have complete information requisite for the follow-up of the
patient. [See WARNINGS AND PRECAUTIONS]
Increased nephrotoxicity can occur with use of standard doses of cyclosporine
in combination with everolimus. Therefore reduced doses of cyclosporine should
be used in combination with everolimus in order to reduce renal dysfunction.
It is important to monitor the cyclosporine and everolimus whole blood trough
concentrations. [See DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS
and CLINICAL PHARMACOLOGY]
An increased risk of kidney arterial and venous thrombosis, resulting in
graft loss, was reported, mostly within the first 30 days post-transplantation.
[See WARNINGS AND PRECAUTIONS]


DRUG DESCRIPTION
Zortress (everolimus) is a macrolide immunosuppressant.
The chemical name of everolimus is
(1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1,
18-dihydroxy-12 -{(1R)- 2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,
17, 21, 23, 29, 35-hexamethyl-11, 36-dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2,
3,10,14,20-pentaone.
The molecular formula is C53H83NO14 and the
molecular weight is 958.25. The structural formula is








Everolimus is supplied as tablets for oral administration containing 0.25 mg,
0.5 mg and 0.75 mg of everolimus together with butylated hydroxytoluene, magnesium
stearate, lactose monohydrate, hypromellose, crospovidone and lactose anhydrous
as inactive ingredients.
Last reviewed on RxList: 5/6/2010





Other reviews about Everolimus on wordpress

Pharma News 3_1
  by Steve Woodruff
Wyeth gets Pristiq approved (a derivative of Effexor) for Major Depressive Disorder. Speaking of anti-depressants, lots of noise being made - and arguments back and forth - about whether […]


Pharma News 9_12
  by Steve Woodruff
King begins hostile takeover proceedings with Alpharma - Brain Markison, King’s ceo, is disappointed that Dean Mitchell, Alpharma’s ceo, hasn’t responded to his initial offer $1.4 billion offer, […]


RAD001 Phase II Trial Results Positive In Patients With Advanced Gastric Cancer After Failure Of One Or More Prior Treatments
  by yestelli
Data released show RAD001 (also known as everolimus; proposed brand name Afinitor(R)) halted tumor growth in 55% of patients with advanced gastric cancer, a condition for which there […]


Boston Scientific Submits Final Modules To FDA For Approval Of Second-Generation Small Vessel And Long Lesion Stents
  by enartion
Boston Scientific Corporation (NYSE: BSX) announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final modules of the Company's Pre-Market Approval (PMA) […]


Boston Scientific Begins Clinical Trial Enrollment For NEW Everolimus-eluting Stent
  by enartion
Boston Scientific Corporation (NYSE: BSX) announced the beginning of patient enrollment in the PLATINUM clinical trial, which is designed to evaluate the Company's PROMUSâ„¢ Elementâ„¢ Everolimus-Eluting Coronary Stent. […]


New phase I/II clinical trial : everolimus and paclitaxel albumin-stabilized nanoparticle in treating breast cancer
  by nanocolors
The Cancer Institute of New Jersey and the National Cancer Institute launched in July 2009 a new phase I/II clinical trial involving a nanoparticle formulation, which is now […]


Are Zotarolimus-Eluting Stents Really Noninferior to Everolimus-Eluting Stents?
  by zedie
Only time will tell. Second-generation drug-eluting stents (DES) are staking their claims to superiority over established DES, but in the recent SORT OUT III trial, a first-generation […]


Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
  by zedie
Background Autosomal dominant polycystic kidney disease (ADPKD) is a slowly progressive hereditary disorder that usually leads to end-stage renal disease. Although the underlying gene mutations were identified […]


Everolimus (Affinitor) Improves Survival in Pancreatic Neuroendocrine Tumors
  by wngai
Pancreatic neuroendocrine tumors affect the hormone-producing tissues within the pancreas, and have an incidence rate, affecting only 2 to 4 people per million worldwide.   The incidence, however, is rising, […]



Other reviews about Everolimus on web:

Everolimus (RAD-001, marketed by Novartis under the tradenames Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and Afinitor in oncology is ... Everolimus - Wikipedia, the free encyclopedia


Everolimus Brand names: Certican® Español: Everolimus, Tableta oral Everolimus Oral tablet What is this medicine? EVEROLIMUS (eve ROE li mus) Everolimus: Information from Answers.com


Information from the FDA about the approval of this drug and the clinical trials that led to the approval. FDA Approval for Everolimus - National Cancer Institute


Buy Everolimus today! Finally Everolimus is availble for purchase at a reasonable price to patients with metatstatic kidney cancer, renal cell carcinoma! Home Page [everolimus.net]


An independent data monitoring committee stopped a major Phase III clinical trial of the investigational drug everolimus (RAD001) after interim results showed significantly better ... Everolimus (RAD001) Significantly Extends Progression-Free ...


This page contains brief information about everolimus and a collection of links to more information about the use of this drug, related news and research results, and ongoing ... Everolimus - National Cancer Institute


All about Everolimus Tablets. View complete and up to date Everolimus information - part of the Drugs.com trusted medication database. Everolimus Tablets Facts and Comparisons at Drugs.com


Everolimus professional patient advice. Specific and up to date information about Everolimus. Complete Everolimus information from Drugs.com


Find information about Afinitor® (everolimus) tablets, the once-daily, oral mTOR inhibitor for advanced renal cell carcinoma treatment after failure of treatment with sunitinib or ... Advanced Renal Cell Carcinoma Treatment | Everolimus Tablets ...


Get Novartis Media Releases through RSS Everolimus (RAD001) significantly extends progression-free ...





Featured Reviews

Reviews Measles, Mumps, and Rubella Virus Vaccine Live

M-M-R II Drug Description M-M-R® II (measles, mumps, and rubella virus vaccine live) DRUG DESCRIPTION What are the possible side effects of measles, mumps, and rubella vaccines (M-M-R II)? You should not receive a booster vaccine...
Read More  |  Review This
Reviews Hydrocodone Bitrate and Acetaminophen Tablets

Vicodin HP Drug Description Vicodin HP® (hydrocodone bitartrate and acetaminophen) 10 mg/660 mg tablets, USP DRUG DESCRIPTION Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration. Hydrocodone...
Read More  |  Review This
Reviews Taxotere

Taxotere Drug Description TAXOTERE (docetaxel) Injection Concentrate, Intravenous Infusion WARNING The incidence of treatment-related mortality associated with TAXOTERE therapy is increased in patients with abnormal liver function,...
Read More  |  Review This
Reviews Priftin

Priftin Drug Description Priftin (rifapentine) Tablets DRUG DESCRIPTION What are the possible side effects of rifapentine (Priftin)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Reviews Zolinza

Zolinza Drug Description ZOLINZA™ (vorinostat) Capsules DRUG DESCRIPTION What are the possible side effects of vorinostat (Zolinza)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....